{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Huo Y"],"funding":["Key Project of Natural Science Foundation of China","Natural Science Foundation of China","the Innovative research team of high-level local universities in Shanghai","National Key Research and Development Program","Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research"],"pagination":["145"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7923532"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(1)"],"pubmed_abstract":["Background
Bi-specific T-cell engager (BiTE) antibody is a class of bispecific antibodies designed for cancer immunotherapy. Blinatumomab is the first approved BiTE to treat acute B cell lymphoblastic leukemia (B-ALL). It brings killer T and target B cells into close proximity, activating patient's autologous T cells to kill malignant B cells via mechanisms such as cytolytic immune synapse formation and inflammatory cytokine production. However, the activated T-cell subtypes and the target cell-dependent T cell responses induced by blinatumomab, as well as the mechanisms of resistance to blinatumomab therapy are largely unknown.Results
In this study, we performed single-cell sequencing analysis to identify transcriptional changes in T cells following blinatumomab-induced T "],"journal":["BMC genomics"],"pubmed_title":["Blinatumomab-induced T cell activation at single cell transcriptome resolution."],"pmcid":["PMC7923532"],"funding_grant_id":["2016YFC0902800","81530006","81870112","2019CXJQ01"],"pubmed_authors":["Lu DR","Yin H","Li CM","Sheng Z","Ellwanger DC","Huo Y","Wang S","Homann O","Ren R"],"additional_accession":[]},"is_claimable":false,"name":"Blinatumomab-induced T cell activation at single cell transcriptome resolution.","description":"Background
Bi-specific T-cell engager (BiTE) antibody is a class of bispecific antibodies designed for cancer immunotherapy. Blinatumomab is the first approved BiTE to treat acute B cell lymphoblastic leukemia (B-ALL). It brings killer T and target B cells into close proximity, activating patient's autologous T cells to kill malignant B cells via mechanisms such as cytolytic immune synapse formation and inflammatory cytokine production. However, the activated T-cell subtypes and the target cell-dependent T cell responses induced by blinatumomab, as well as the mechanisms of resistance to blinatumomab therapy are largely unknown.Results
In this study, we performed single-cell sequencing analysis to identify transcriptional changes in T cells following blinatumomab-induced T ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2026-05-01T11:17:32.666Z","creation":"2021-03-05T09:12:15Z"},"accession":"S-EPMC7923532","cross_references":{"pubmed":["33648458"],"doi":["10.1186/s12864-021-07435-2"]}}